Showing 2961-2970 of 5972 results for "".
- Galderma to Begin Two Phase III Restylane Trialshttps://practicaldermatology.com/news/galderma-to-begins-two-phase-iii-restylane-trials/2458679/Galderma is set to initiate a pivotal Phase III trial on Restylane® Lyft for hand augmentation and another that will look to the safety of Restylane® Silk when ad
- WHO: Improved Access to Psoriasis Treatments Neededhttps://practicaldermatology.com/news/who-improved-access-to-psoriasis-treatments-needed/2458685/Key stakeholders including policy makers, physicians and patients must come together to turn the corner on psoriasis, according to the World Health Organization’s (WHO) new Globa
- New Initiative Seeks To Raise Biosimilar Awareness, Accesshttps://practicaldermatology.com/news/new-initiative-to-raise-biosimilar-awareness-access/2458689/The Biosimilars Forum is launching a new biosimilars education initiative. The Partnership for Biosimilars Education and Access will focus on raising awareness and encouraging access to biosimilars in the United States. The Forum
- Endo International Launches New Phase 2b Study of CCH for Cellulitehttps://practicaldermatology.com/news/endo-international-launches-new-phase-2b-study-of-cch-for-cellulite/2458699/A Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of as cellulite is about to get started, Endo International plc reports. CCH is intended to target and lyse collagen tethers with the goal of releasing the skin di
- Interferon Not Beneficial for Most Stage III Melanomahttps://practicaldermatology.com/news/interferon-not-beneficial-for-most-stage-iii-melanoma/2458703/Most stage III melanoma patients do not benefit from treatment with interferon, according to final results for the Sunbelt Melanoma Trial, published online in the Jour
- ZELTIQ® Taps Todd Zavodnick as New President, Internationalhttps://practicaldermatology.com/news/zeltiq-taps-todd-zavodnick-as-new-president-international/2458708/Todd Zavodnick is the new President, International of ZELTIQ®. Mr. Zavodnick will be responsible for driving the company’s international growth and expansion. He rec
- Novan Announces Robert A. Ingram as Chairmanhttps://practicaldermatology.com/news/novan-announces-robert-a-ingram-as-chairman/2458716/Novan, Inc. named Robert A. Ingram as Chairman of the Board of Directors of Novan. In addition, Robert Keegan has been appointed to the Board of Directors. The company also announced that it received $32.8 million of net proceeds in a private Mezzanine B financing in December 2015 from it
- Study Shows Novel Effects of Eucerin Active Ingredient Complex on Atopic Dermatitishttps://practicaldermatology.com/news/study-shows-novel-effects-of-eucerin-active-ingredient-complex-on-atopic-dermatitis/2458717/Beiersdorf researchers in collaboration with the Dermatological Clinic of the University of Lübeck have shown in a double-blind clinical study that the AtopiControl ingredient complex including licochalcone, a from the licorice root and omega-6 fatty acids from evening primros
- FDA Issues Consumer Warning about Crema Piel De Seda (Silky Skin Cream) by Viansilk: Risk of Mercury Poisoninghttps://practicaldermatology.com/news/fda-issues-consumer-warning-about-crema-piel-de-seda-silky-skin-cream-by-viansilk-risk-of-mercury-poisoning/2458725/The FDA warned consumers not to purchase or use a skin whitening cream called “Crema Piel De Seda,” due to the risk of mercury poisoning. FDA laboratory analysis identified mercury in the product. Exposure to mercury can cause serious health problems, such as kidney and nervous system
- Study: Women Younger than 40 at Melanoma Diagnosis Indoor Tanned Earlier, Morehttps://practicaldermatology.com/news/study-women-younger-than-40-at-melanoma-diagnosis-indoor-tanned-earlier-more/2458731/Melanoma among younger individuals is on the rise, and now new research suggests that initiating indoor tanning at an earlier age and more frequent tanning may be to blame. In the study, women younger than 40 when diagnosed with melanoma reported initiating indoor tanning at an earlier ag